Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable

Published: 11 February 2022
Myeloma cells
Multiple myeloma is a cancer that forms in a type of white blood cell

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable informed by a report produced by SHTAC.

NICE’s guidance recommends:

Daratumumab plus bortezomib, thalidomide and dexamethasone is recommended, within its marketing authorisation, as induction and consolidation treatment for untreated multiple myeloma in adults, when an autologous stem cell transplant is suitable. It is recommended only if the company provides daratumumab according to the commercial arrangement.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research on multiple myeloma please visit our Research page.

 

Privacy Settings